Monitoring of anti-TNF biological treatments
暂无分享，去创建一个
D. Nagore | A. Balsa | D. Pascual‐Salcedo | L. Simón | I. Ramos | A. Ruiz del Agua | S. Ramiro | A. Martínez | L. Novalbos
[1] L. Aarden,et al. Dealing with immunogenicity of biologicals: assessment and clinical relevance , 2009, Current opinion in rheumatology.
[2] P. V. van Riel,et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis , 2008, Annals of the rheumatic diseases.